Emerald Advisers LLC Raises Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

Emerald Advisers LLC raised its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 57.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 244,633 shares of the company’s stock after purchasing an additional 89,088 shares during the quarter. Emerald Advisers LLC owned approximately 0.60% of Keros Therapeutics worth $3,873,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Geode Capital Management LLC grew its position in shares of Keros Therapeutics by 6.8% in the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock worth $42,146,000 after buying an additional 46,041 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Keros Therapeutics by 14.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock worth $15,105,000 after buying an additional 32,492 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Keros Therapeutics in the 4th quarter worth about $388,000. Barclays PLC grew its position in shares of Keros Therapeutics by 140.1% in the 3rd quarter. Barclays PLC now owns 60,014 shares of the company’s stock worth $3,484,000 after buying an additional 35,022 shares during the period. Finally, Intech Investment Management LLC purchased a new stake in shares of Keros Therapeutics in the 3rd quarter worth about $603,000. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Stock Performance

KROS opened at $11.22 on Monday. The stock has a market capitalization of $455.11 million, a P/E ratio of -2.15 and a beta of 1.39. The company’s 50-day simple moving average is $11.18 and its two-hundred day simple moving average is $35.80. Keros Therapeutics, Inc. has a 52-week low of $9.78 and a 52-week high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.36) by $0.22. The business had revenue of $3.04 million for the quarter, compared to analysts’ expectations of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Research analysts forecast that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on KROS. Wedbush downgraded shares of Keros Therapeutics from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $47.00 to $15.00 in a research report on Friday, January 17th. Cantor Fitzgerald downgraded shares of Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 21st. BTIG Research downgraded shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. HC Wainwright cut their price objective on shares of Keros Therapeutics from $47.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. Finally, Scotiabank cut their price objective on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a research report on Thursday, January 16th. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $42.33.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.